A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

por Zelek, L, Yovine, A, Brain, E, Turpin, F, Taamma, A, Riofrio, M, Spielmann, M, Jimeno, J, Misset, J L
Publicado 2006

Contribution of the d-Serine-Dependent Pathway to the Cellular Mechanisms Underlying Cognitive Aging

por Potier, B., Turpin, F. R., Sinet, P.-M., Rouaud, E., Mothet, J.-P., Videau, C., Epelbaum, J., Dutar, P., Billard, J.-M.
Publicado 2010

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

por Delord, J P, Pierga, J Y, Dieras, V, Bertheault-Cvitkovic, F, Turpin, F L, Lokiec, F, Lochon, I, Chatelut, E, Canal, P, Guimbaud, R, Mery-Mignard, D, Cornen, X, Mouri, Z, Bugat, R
Publicado 2005